⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCRX News
BioCryst Pharmaceuticals Inc
ADARx Pharmaceuticals Appoints Donald Fong, M.D., as Chief Medical Officer
globenewswire.com
BCRX
ANNX
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
globenewswire.com
BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BCRX
CD137 Targeted Therapy Research Report 2026-2030: Market Opportunities, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insights - ResearchAndMarkets.com
businesswire.com
GMAB
ABL
BNTX
BCRX
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
globenewswire.com
BCRX
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
globenewswire.com
BCRX
Astria Stockholders Vote to Approve Acquisition by BioCryst
businesswire.com
ATXS
BCRX
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
globenewswire.com
BCRX
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
prnewswire.com
ATXS
BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BCRX